How do pharma and biotech companies build a CMC strategy that accelerates marketing authorization rather than slowing it down?

Chemistry, Manufacturing and Controls rarely slows authorizations down because a single data requirement is missing, but because the workstreams are tackled in the wrong order. Three decisions carry across the entire lifecycle: the formulation, the manufacturing process and the supplier selection. They all end up in CTD Module 3 and must be scientifically justified against the Quality by Design logic of ICH Q8, Q9 and Q10. Companies that make these determinations only after the clinical phase has begun turn them into a bottleneck, because in the worst case every later change brings new stability data, a renewed process validation and a variation in its wake.

This is exactly where we come in: the CMC strategy makes visible early on which determination is critical, before the dossier is written and the process is validated at commercial scale. This shifts the effort forward, to where changes are inexpensive. The same bottleneck becomes visible during tech transfer: if the validated production process deviates from the submitted development process, a gap opens up between the dossier and reality. After authorization, every correction then becomes a variation under (EC) No 1234/2008, which usually runs as an approval-requiring Type II change rather than a simple internal adjustment.